Literature DB >> 3492629

Treatment of aplastic anemia with cyclosporin A, methylprednisolone, and antithymocyte globulin.

N Frickhofen, W Heit, A Raghavachar, F Porzsolt, H Heimpel.   

Abstract

Twenty-three patients with aplastic anemia (18/23 with severe aplastic anemia) were treated with an immunosuppressive regimen consisting of cyclosporin A (CsA) and methylprednisolone (MP) (n = 7) or CsA, MP, and antithymocyte globulin (ATG; n = 16). Nineteen patients are alive with a follow-up of 4 to 25 months; three patients died of infections and one of a gastrointestinal hemorrhage. Within 3 months, improvement of hematopoiesis was seen in 14 patients (61%). First signs of a response after 23 to 88 days were followed by complete remission in eight patients, partial remission in three patients, and minimal improvement in three patients. Two of the patients with only minimal improvement were treated with a second course of immunosuppression and reached a complete remission and partial remission. Interestingly, remission proved to be dependent on the continued administration of CsA in four of five patients with partial or complete remission who could be evaluated up to now. Thus, CsA must have been effective in the induction and/or maintenance of remission in three patients. This observation is a very strong argument for the role of T cells in the pathogenesis of at least some cases of aplastic anemia and warrants further evaluation of the role of CsA in the treatment of aplastic anemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492629     DOI: 10.1007/BF01728454

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells.

Authors:  D J White; A M Plumb; G Pawelec; G Brons
Journal:  Transplantation       Date:  1979-01       Impact factor: 4.939

2.  A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia.

Authors:  B M Camitta; E D Thomas; D G Nathan; R P Gale; K J Kopecky; J M Rappeport; G Santos; E C Gordon-Smith; R Storb
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

3.  Cyclosporine in refractory severe aplastic anemia.

Authors:  F Wisløff; H C Godal
Journal:  N Engl J Med       Date:  1985-05-02       Impact factor: 91.245

4.  Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.

Authors:  R Champlin; W Ho; R P Gale
Journal:  N Engl J Med       Date:  1983-01-20       Impact factor: 91.245

5.  Immunosuppressive therapy of severe aplastic anemia.

Authors:  K C Doney; B Torok-Storb; S Dahlberg; C D Buckner; P Martin; J A Hansen; E D Thomas; R Storb
Journal:  Prog Clin Biol Res       Date:  1984

6.  Cyclosporine and graft failure following bone marrow transplantation for severe aplastic anaemia.

Authors:  J Hows; S Palmer; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1985-08       Impact factor: 6.998

7.  Cyclosporin A in the treatment of severe acute aplastic anaemia.

Authors:  P Jacobs; L Wood; R W Martell
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

8.  Generation of CFU-c suppressor T cells. VI. Effect of cyclosporin A.

Authors:  M Podestà; A Bacigalupo; F Frassoni; M R Raffo; G Piaggio; M Repetto; M T Van Lint; A Marmont
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

9.  Analysis of cloned T cell function. II. Differential blockade of various cloned T cell functions by cyclosporine.

Authors:  C G Orosz; D C Roopenian; M B Widmer; F H Bach
Journal:  Transplantation       Date:  1983-12       Impact factor: 4.939

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  4 in total

1.  Cyclosporin A in aplastic anemia--report of a workshop.

Authors:  H Schrezenmeier; M Schlander; A Raghavachar
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Immunosuppressive treatment of aplastic anemia: a prospective, randomized multicenter trial evaluating antilymphocyte globulin (ALG) versus ALG and cyclosporin A.

Authors:  N Frickhofen; J P Kaltwasser
Journal:  Blut       Date:  1988-04

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia.

Authors:  M Peters; M Trippler; H Löhr; W Gödderz; W Herr; S Störkel; K H Meyer zum Büschenfelde; G Gerken
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.